KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
Holding KALV?
Track your performance easily

KalVista Pharmaceuticals (KALV) Ownership - Who Owns KalVista Pharmaceuticals?

380 Followers

KalVista Pharmaceuticals (KALV) Ownership Overview

11.35%15.02%4.56%9.59%59.49%
11.35% Insiders
4.56% Other Institutional Investors
9.59% ETFs
59.49% Public Companies and
Individual Investors
The ownership structure of KalVista Pharmaceuticals (KALV) stock is a mix of institutional, retail, and individual investors. Approximately 29.16% of the company’s stock is owned by Institutional Investors, 11.35% is owned by Insiders, and 59.49% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Feb 16, 2024
xxxxxxxxxxxxx
$612825
Feb 16, 2024
xxxxxxxxxxxxx
$598290
Feb 16, 2024
xxxxxxxxxxxxx
$422565
Feb 16, 2024
xxxxxxxxxxxxx
$875340

Recent Hedge Fund Trading Activity

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
4,824,731Insider9.90%55,050,181
3,227,620Institution6.63%36,827,144
2,022,076Institution4.15%23,071,887
1,783,605Institution3.66%20,350,933
1,642,102Institution3.37%18,736,384
553,720Institution1.14%6,317,945
535,717Institution1.10%6,112,531
500,000Institution1.03%5,705,000
434,248Institution0.89%4,954,770
341,503Institution0.70%3,896,549

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
3,227,620Institution6.63%36,827,144
1,642,102Institution3.37%18,736,384
434,248Institution0.89%4,954,770
341,503Institution0.70%3,896,549
310,823Institution0.64%3,546,490
278,261Institution0.57%3,174,958
194,062Institution0.40%2,214,247
189,231Institution0.39%2,159,126
127,300Institution0.26%1,452,493
110,720Institution0.23%1,263,315

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
1,199,834Institution2.46%13,894,078
1,032,230Institution2.12%11,777,744
565,016Institution1.16%6,542,885
494,246Institution1.01%5,525,670
351,562Institution0.72%4,011,322
210,000Institution0.43%2,396,100
176,751Institution0.36%2,046,777
87,630Institution0.18%999,858
77,633Institution0.16%867,937
63,809Institution0.13%713,385

FAQ

Who Owns KalVista Pharmaceuticals (KALV)?
According to the latest TipRanks data, approximately 4.56% of the company's stock is held by institutional investors, 11.35% is held by insiders, and 59.49% is held by retail investors.
    What percentage of KalVista Pharmaceuticals (KALV) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 4.56% of KalVista Pharmaceuticals (KALV) stock is held by institutional investors.
      What percentage of KalVista Pharmaceuticals (KALV) stock is held by retail investors?
      According to the latest TipRanks data, approximately 59.49% of KalVista Pharmaceuticals (KALV) stock is held by retail investors.
        Who owns the most shares of KalVista Pharmaceuticals (KALV)?
        Venrock Healthcare Capital Partners III, L.P. owns the most shares of KalVista Pharmaceuticals (KALV).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis